Pfizer (PFE) TALZENNA® Study Results: price prediction tomorrow

Published Wednesday, 25 March 2026

News Context

Pfizer Inc. (NYSE: PFE) has reported positive topline results from its Phase 3 TALAPRO-3 study, evaluating TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) for patients with homologous recombination repair (HRR) deficient metastatic castration-resistant prostate cancer (mCRPC). This announcement, as reported by Yahoo Finance, marks a significant development within Pfizer's oncology pipeline, potentially expanding treatment options for a specific prostate cancer patient population. This positive clinical trial outcome follows a period where Pfizer's oncology segment has been a focus, with company executives highlighting recent milestones. In the broader pharmaceutical landscape, competitive developments such as Bristol Myers Squibb's (BMY) Opdivo label expansion, also noted by Yahoo Finance, illustrate the dynamic nature of the oncology market. However, the direct positive data from Pfizer's TALAPRO-3 study provides a distinct catalyst for the company's specific drug portfolio.

MC AI Analysis

MarketCrunch AI analysis indicates a complex pattern for PFE following the positive news. The AI model, incorporating over 732,000 data points, projects a next-session price target of approximately $26.99895, representing a potential change of -1.14% from the current close of $27.31. This prediction is generated with a high confidence level of 22.17%. Despite the 'Very Bullish' news sentiment (score 0.9236) associated with the TALZENNA® study results, the short-term price model suggests a modest downward adjustment. This divergence between positive fundamental news and the immediate price forecast may be attributed to the interplay of various technical factors and prior market dynamics. The model's meta-commentary highlights conflicting signals, with technical indicators leaning bullish but with limited conviction, while the AI model's short-term price target suggests otherwise. This environment may favor a patient approach, awaiting clearer directional resolution. It is also observed that consistent, material insider selling by executives throughout early 2024 has been a factor, potentially weighing on near-term price momentum.

Technical Snapshot

Analysis of PFE's technical indicators reveals a mixed but generally supportive underlying structure, albeit with nuanced directional signals. Short-term momentum, as indicated by the Tenkan_sen and 5-period simple moving average, suggests upward pressure. The long-term trend, evidenced by the 200-period simple moving average, also indicates a sustained bullish conviction, with the price trading above this key level. The MACD indicator points to positive trend and momentum. However, the 14-period Relative Strength Index (RSI) is observed to be pulling the price down, suggesting the asset is not in an oversold condition. Volatility is currently assessed as moderate, with Bollinger Bands indicating a relatively tight range. The Average Directional Index (ADX) signals high trend strength, but the directional index spread is negative, implying less clarity on the immediate trend direction despite its strength. The end-of-week forecast projects a price range between $26.51 and $27.81, with a predicted close near $27.20, providing a broader context for the next-day's potential movement.

What to Watch

For short-term observation, monitoring PFE's price action relative to its immediate support and resistance levels is indicated. The AI model's projected next-day price target near $27.00 will be a key level to assess. Further information on the TALAPRO-3 study's full data presentation or regulatory filings could serve as future catalysts. Traders may observe volume patterns around the current price levels for indications of conviction behind price movements. The interplay between the positive news flow, the AI model's short-term price projection, and the underlying technical structure suggests a need for careful pattern recognition in the immediate sessions. View the full AI forecast for PFE

Cover: Photo by Tima Miroshnichenko on Pexels.